Triglyceride-lowering genes involved in intravascular lipolysis, including intravascular lipoprotein lipase (LPL) and its inhibitor angiopoietin-like 4 (ANGPTL4), have been associated with lower risk of T2D [35••, 60••], while triglyceride-lowering variants in genes involved in the hepatic production of triglyceride-rich lipoprotein particles were linked to higher risks of diabetes and fatty liver [60••]. Here, ANGPTL4 is linked to type 2 diabetes mellitus.